## **EmbryoMap QC Guidance**

This technical note provides guidance ranges for key metrics of the EmbryoMap solution. It also outlines the various factors affecting the key metrics and includes steps for troubleshooting

### Introduction

The EmbryoMap Sample Prep system simultaneously amplifies DNA from a group of cells (3-10) and prepares sequencing ready libraries for Illumina platforms. This document is intended to assist in the assessment of whether the prepared libraries and the sequencing run are within the laboratory validated sample metric ranges (Guidance ranges are shown in Table 1) when laboratories are validating their sample collection, transportation, amplification/library preparation and sequencing processes. Refer to the **EmbryoMap Sample Prep Guide** and the **EmbryoMap eMap Software Guide** for more information on how to perform the test and analyse the results.

### Sample input recommendations

All biopsy samples for EmbryoMap processing must be suspended in molecular grade 1× PBS (Phosphate Buffered Saline) and, if used, with a maximum concentration of 0.5% PVP (Polyvinylpyrrolidone) in a total

volume of 2.5 µl. Biopsy stability under storage and shipment conditions used (including any alternative sample collection volume, wash or collection buffers) must be fully validated by the user before use and may impact the quality and integrity of the biopsy samples, leading to suboptimal library quality that may compromise your test results.

### **EmbryoMap amplification**

Incorporation of extraneous material containing DNA prior to amplification can lead to misleading results. This is a concern with any DNA amplification technology. Pre-PCR environmental and sampling control measures (i.e., single use of molecular grade reagents and consumables) are required to reduce the risk of sample contamination prior to input into the EmbryoMap amplification reactions. Failure to follow Pre-PCR best practices during the reaction setup may lead to contamination of the PCR products, affecting subsequent analysis and/or compromise your test results.

#### **Human DNA contamination**

Contamination with human DNA can obscure the aneuploidy status of the tested sample or lead to shifts in sex chromosome calling. The sequencing reads of human DNA contamination will also map to the human genome and the system cannot distinguish it from the DNA of the samples. The extent to which the test results are compromised depends on the amount of human DNA contamination present in the samples.

Technote: EmbryoMap QC Guidance

#### Non-human DNA contamination

Incorporation Microorganism contamination can occur during the embryo biopsy process, from non-sterile reagents or equipment, or even airborne DNA. These extraneous materials will produce PCR products that will generate sequenceable libraries.

The resulting sequencing reads will not map against the human genome database and will be filtered by the system. When the number of reads generated by the contaminant(s) is elevated, it may decrease the reads of the sample below your validated sample metric ranges (Guidance ranges are described in Table 1). This may compromise your test results due to the reduction in usable reads.

#### **Identification of contaminants**

When contamination is suspected, sequencing can be used to confirm the presence or absence of extraneous DNA. For the investigation and identification of the contaminants, a 2x75 cycle or 2x100 cycle sequencing run can be performed on the libraries in question with the MiSeq Reagent Kit v3. Set up a sequencing run using the Library QC workflow from the Illumina Experiment Manager, as described in the MiSeq System User Guide (Illumina Part # 15027617).

Metagenomic apps can be used on Illumina BaseSpace Sequence Hub for the analysis of contaminants. BaseSpace Sequence Hub offers a wide variety of next generation sequencing (NGS) data analysis apps that are developed or optimised by Illumina and a growing ecosystem of third-party app providers.

### **EmbryoMap amplification products**

EmbryoMap amplification of genomic DNA generates PCR products between approximately 0.2 to 2.5 kb. After Size Selection library fragments are optimised for Illumina sequencing, with a median fragment length of 550 bp. This can be seen in Figure 1.




Figure 1: Fragment analysis of EmbryoMap Library Amplification products Pre- and Post- Size Selection.

Fluorometric quantification of **Size Selected** library duplex DNA shall result in positive amplification yield for an input mass of 60 pg or 5-cell isolates that is clearly separable from the yield of 'no template control' (NTC) samples. NTC or suspected amplification failures shall produce fluorescence that is equivalent to the background of the quantification kit.

NTC or suspected amplification failures may still be sequenced in an EmbryoMap run. During preparation of the 'Pooling Guide', select the **'Default'** pooling volume checkbox to include a nominal 5 µl of these samples into the final library pool. Similarly, if contamination is suspected, the NTC sample should be sequenced and reads associated with the sample's unique index should be interrogated to identify the source of contamination.


## Library handling and sequencing

The eMap Software can help to assess the quality of data on two different levels, at the sequencing run (flow cell) level (Figure 2) or at a sample level (Figure 3).

## **Sequencing run-level metrics**

The percentage of successful clusters is shown by Clusters Passing Filter (%). A low percentage of clusters PF might indicate that the amount of DNA loaded onto the instrument requires optimisation for subsequent sequencing runs.

The number of successful reads is shown by Total reads passing filter. Low reads passing filter might indicate low library quality or the presence of non-human DNA contamination.



**Figure 2:** Example of eMap Software sequencing measurements.

## **Sample-level metrics**

The Sample QC tab provided by the eMap Software displays metrics describing the quality of the data for each sample as it is processed from initial base calling to alignment, filtering, and copy-number calling. Reads that pass filters in the copy-number calling algorithm are indicated by 'Number of reads after filtering' in the eMap Software. The key sample-level metrics (colour shaded) are automatically checked against user-specified acceptance criteria specified in the eMap account Settings page (Figure 4).

Idiogram	Sample QC	Experimental details	
SAMPLE ID ①		Sample-01	
QC STATUS ①		PASS	
AVERAGE ALIGNMENT SCORE ②		57.1	
NUMBER OF TOTAL READS ②		912,379	
NUMBER OF MAPPED READS ①		897,886	
NUMBER OF READS AFTER FILTERING ①		771,261	
OVERALL NOISE ①		0.19	
SD ROBUST ②		0.21	
SDI ②		0.83	

**Figure 3:** eMap sample-level metrics. Coloured shading indicates where metrics have been compared to the thresholds specified.

#### **QC** status

The overall QC status is set to PASS or FAIL by default according to the sample-level QC criteria specified in the eMap account Settings. The QC Status can be manually changed by the user during the sample sign off procedure.



**Figure 4**: eMap Software sample-level quality control criteria may be customised by the user in account Settings. Quality criteria are used for automatic sample-level QC flagging and status.

### **Average Alignment Score**

The alignment software calculates this score and considers the base quality score (Q-score), read length, and the number of alignments for every read. The Q-score is a measure of confidence in the base that was called at a given position. The Q-score is calculated as mean (mean [Phred33-based base quality] per read) for all reads per sample.

## **Total Number of Reads (Mapped Reads)**

The run-level metrics described above can be used to check whether the libraries have been pooled in relatively equal proportions for sequencing. The typical total number of reads per sample range from 1.5% to 4.0% of reads passing filter for 48-plex sequencing runs. The guidance range of the total reads and reads after filtering is described in Table 1.

Low values of Mapped (aligned) reads and Reads after filtering might indicate the presence of non-human reads in your DNA source, or an elevated proportion of PCR artefacts caused by suboptimal amplification and library preparations. It is expected that out of ~50 million paired-end reads per sequencing run, several hundred reads may randomly align against random sequences.

### **Overall Noise (DLR-Derivative Log Ratio)**

The overall sample noise measures the spread of the difference in copy number values between all bins of a chromosome. High DLR values might indicate low quality sample DNA or problems during the amplification or library preparation steps.

### **SDI Noise**

The Summed Deviation to nearest Integer metric describes the step-wise noise across all chromosomes in a sample. CNV charts with high SDI values are more challenging to interpret for chromosome-level copy-number.

## Sequencing issues

You can perform a more detailed analysis of your data using Illumina's Sequence Analysis Viewer (SAV) to troubleshoot the most common sequencing problems. If your run does not meet your expected run metrics, you should monitor the following sequencing metrics:

- For hardware and software performance of the instrument, a PhiX validation run needs to be performed in accordance with the MiSeq System guide (part# 15039740) and MiSeq System User Guide (Part # 15027617).
- See the Illumina bulletins What is the PhiX Control v3 Library and what is its function in Illumina Next Generation Sequencing? and How to set up the sample sheet for a PhiX validation run on the MiSeq system using Illumina Experiment Manager for additional information.
- The EmbryoMap recipe is a custom recipe designed for paired-end (2×36 bp), dual-index read sequencing of libraries prepared with the EmbryoMap Sample Prep kit only. This recipe is not suitable to assess the MiSeq instrument hardware and software performance.
- Note that the EmbryoMap Q30 metrics vary based on the library pool quality, cluster density, and the percentage of clusters passing filter.
- To assess the sample level performance, refer to your validated sample metric ranges (See Table 1 for guidance ranges).

### **Cluster Density**

When assessing the quality of your EmbryoMap run, first check the cluster density against your validated sample metric ranges (Guidance ranges are described in Table 1). If optimisation is required, please refer to the Cluster Optimization guide (Illumina Part #100000071511).

When performing the Template Line Wash, it is important that the correct concentration and volume (1 mL) of NaOCI is used. If the concentration or volume used is too high, it can impact subsequent runs by impeding cluster generation or even complete failure to generate clusters.

Technote: EmbryoMap QC Guidance

#### **Flow Check Error**

If the MiSeq fails to measure the flow rate while starting a run, inspect the gasket of the flow cell for any damage that may have occurred during cleaning. Please see the Illumina bulletin What should I do if my MiSeq fails to measure flow rate when starting a run? for additional information.

Clean the flow cell as described in the MiSeq System User Guide. Not adhering to the flow cell best cleaning practices might raise or distort the gasket, causing flow check errors

Metrics	Parameters	Guidance Range	Sources of Values
Amplification Test	Concentration of dsDNA ng/µl (5-cells)	5-15	Final library quantification after Size Selection step
Flow cell level metrics	Density (K/mm²)	1,100-1600	MiSeq instrument screen Display, eMap Run QC page, Illumina SAV software
	Total number of reads	50,000,000	
	Total number of reads (PF)	38,000,000	
	% of clusters passing filter ≥75%		
Sample level metrics	Total number of reads ≥300,000		
	Number of reads after filtering	≥200,000	Downstream analysis in eMap software
	Average quality score	≥50	
	Overall noise (DLR)	≤0.4	
	SDI noise	≤4.5	
Chromosome- level metric	Region confidence (value in regions tab)	≥0.70	

Table 1: EmbryoMap MiSeq flow cell and sample guidance QC metrics

**Note:** The above metrics are guidance ranges. Individual laboratories must validate their own sample metric ranges in accordance with their quality management system to ensure that they meet their performance and specification requirements.